Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	37.53B
Revenue (ttm)	25.44B
Net Income (ttm)	190.49M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	197.01
Forward PE	n/a
Dividend	1.17 (5.05%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	351
Open	23.22
Previous Close	23.26
Day's Range	23.22 - 23.45
52-Week Range	22.45 - 28.29
Beta	n/a
RSI	42.03
Earnings Date	Oct 30, 2025

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY